The company upsized its convertible senior notes offering to $140 million from the previously announced $120 million. The 5.25% notes will mature on December 1, 2030. Additionally, T1 Energy priced 28 ...

(RTTNews) - T1 Energy Inc. (TE) announced the pricing of its underwritten public offerings, which include $140.0 million aggregate principal amount of 5.25% convertible senior notes due 2030 and 28.28 ...

Farran Powell is the managing editor of investing at Forbes Advisor. She was previously the assistant managing editor of investing at U.S. News & World Report. Her work has appeared in numerous ...

Zoetis Inc. (NYSE:ZTS) is among the 11 Most Oversold S&P 500 Stocks Heading into 2026. On December 10, HSBC slashed its price target on the stock to $140 from $180, as part of the firm’s broader ...

Mizuho also raised its price target on Gilead to $140.00, maintaining an Outperform rating, citing a longer exclusivity period for Biktarvy following litigation settlements. Additionally, Gilead ...

Farran Powell is the managing editor of investing at Forbes Advisor. She was previously the assistant managing editor of investing at U.S. News & World Report. Her work has appeared in numerous ...

If you are wondering whether Tower Semiconductor is still a smart buy after such a huge run up in its share price, or if you might be late to the party, this article will break down what the current ...

The goal is to help shoppers track the change in prices over time and make a decision about where to shop each week. It will cost you more across the board for groceries this week. The average cost of ...

Choose options to include in this vehicle value. (*)Includes the value of the outboard motor and trailer. Only select options that are in addition to standard equipment and equipment noted in the ...

HSBC lowered the firm’s price target on Zoetis (ZTS) to $140 from $180 and keeps a Buy rating on the shares as part of a 2026 outlook for the pharma group. The firm believes the sector is well ...

Guggenheim analyst Seamus Fernandez raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $140 from $120 and keeps a Buy rating on the shares. Last week’s preliminary Prader-Willi ...